Dubois, PANCT07284602Now EnrollingIRB Ready

Idiopathic Pulmonary Fibrosis (IPF) Clinical Trial in Dubois, PA

Access cutting-edge idiopathic pulmonary fibrosis (ipf) treatment through this phase 3 clinical trial at a research site in Dubois. Study-provided care at no cost to qualified participants.

Sponsored by PureTech

Quick Self-Assessment

See if you qualify for this Dubois location

Preparing your pre-screening questions…

Expert Care in Dubois

Access idiopathic pulmonary fibrosis (ipf) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related idiopathic pulmonary fibrosis (ipf) treatment provided free

Apply for This Dubois Location

Check if you qualify for this idiopathic pulmonary fibrosis (ipf) clinical trial in Dubois, PA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Dubois

    Convenient for PA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Dubois site if eligible
  4. 4Begin participation

About This Idiopathic Pulmonary Fibrosis (IPF) Study in Dubois

This is a study for adults with a lung disease called idiopathic pulmonary fibrosis. The main purpose of this study is to look at how well deupirfenidone improves lung function and how safe it is for people with idiopathic pulmonary fibrosis (IPF) when compared with pirfenidone. Participants may have been treated with an approved antifibrotic drug for up to a year in the past, but they cannot be on background antifibrotic treatment during this study. Participants will be randomly assigned (meaning by chance) to take either deupirfenidone or pirfenidone 3 times a day, and neither a participant nor their study team will know which study drug participants are on. Participants will be in the study for up to approximately 3 years. During the first year, participants visit the study site up to ten times and afterwards they visit the site every three months. All participants will remain on blinded study drug until the last participant has completed Week 52 Visit. They will have lung function tests, a check of their health, and will tell the study team about any unfavorable effects.

Sponsor: PureTech

Who Can Participate

Inclusion Criteria

Is ≥40 years of age at the time of informed consent.
Meets the diagnostic criteria of IPF American Thoracic Society (ATS)/European Respiratory Society (ERS)/Japanese Respiratory Society (JRS)/Latin American Thoracic Society (ALAT) 2022 guidelines.
Has a maximum time from initial IPF diagnosis of 7 years.
Has no prior exposure to pirfenidone or LYT-100.
Has definite or probable unusual interstitial pneumonia (UIP) on HRCT, performed within 12 months prior to Visit 1 and confirmed by the central reader.
Has an FVC ≥45% of predicted normal at Visit 1.

Exclusion Criteria

Has, in the opinion of the Investigator, significant clinical worsening of IPF between Visit 1 and Visit 2 (eg, clinically significant hospitalization, clinically significant respiratory event).
Has been hospitalized within 3 months prior to Visit 1 for acute exacerbation of IPF or other significant respiratory complication.
Has prebronchodilator forced expiratory volume in 1 second (FEV1)/FVC \<0.7 at Visit 1.
Has a greater extent of emphysema vs fibrosis on the most recent HRCT scan as confirmed by the central reader.
Has a diagnosis of any condition that could be an explanation for interstitial lung disease (ILD).
Has a major extrapulmonary condition that could affect spirometry.
Has a current diagnosis of other relevant respiratory disorders.
Has significant pulmonary hypertension (PH).
Has had a lung transplant.
Has cardiovascular disease.
Has underlying chronic liver disease/impairment.
Has relevant chronic or acute infections including active viral hepatitis or poorly controlled HIV.
Has had any major surgical procedures performed within 6 weeks prior to Visit 1 or is planning to have a major surgical procedure during the study.
Has any documented active or suspected malignancy or history of malignancy within 5 years prior to Visit 1.
Has any of the following laboratory abnormalities at Visit 1:
Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) \>1.5 × upper limit of normal (ULN).
Total bilirubin \>1.5 × ULN. Exceptions may be made on a case-by-case basis for participants with Gilbert's syndrome in consultation with the Medical Monitor.
Creatinine clearance \<30 mL/min calculated by Cockcroft-Gault formula.
Is currently taking prednisone at a steady dose \>10 mg/day or equivalent (a steady dose ≤10 mg/day is not exclusionary but the individual must be on a stable dose for at least 30 days prior to Visit 2).
Use of any tobacco or combustible cannabis products within 3 months prior to Visit 1 or is unable to refrain from use during the trial.
Has known symptoms of dysphagia, difficulty in swallowing capsules or tablets, or has had a total gastrectomy.
Is currently enrolled in another clinical study (except observational/registry or biobank studies) or has used any investigational drug or device within 90 days prior to Visit 1.
Has ever received stem cell therapy for the treatment of pulmonary fibrosis.
Is currently pregnant, breastfeeding, or is planning to become pregnant during the study.
Has had any prior exposure to LYT-100 or pirfenidone (even one dose).

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Dubois?

Yes, this clinical trial (NCT07284602) has an active research site in Dubois, PA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Idiopathic Pulmonary Fibrosis (IPF) Treatment Options in Dubois, PA

If you're searching for idiopathic pulmonary fibrosis (ipf) treatment options in Dubois, PA, this clinical trial (NCT07284602) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Dubois research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced idiopathic pulmonary fibrosis (ipf) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all idiopathic pulmonary fibrosis (ipf) clinical trials near you to find additional studies recruiting in your area.

More Pulmonary Fibrosis Trials in Dubois, PA

See all pulmonary fibrosis clinical trials recruiting in Dubois — not just this study.

Browse Pulmonary Fibrosis Trials in Dubois →

Browse More Trials by Condition

Pulmonary Fibrosis TrialsInterstitial Cystitis TrialsFibromyalgia TrialsInterstitial Lung Disease TrialsAll Conditions →

Ready to Join in Dubois?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Dubois, PA